Intellia Therapeutics, Inc. · Transaction Feb 28, 2022 · Filed Mar 3, 2022 · $15,001 to $50,000
NASDAQ NMS - GLOBAL MARKET · NTLA
+3.83% · +$0.4700 · Vol 5.0M
After hours · updated 18:49:25 ET
Intellia Therapeutics Inc
Biotechnology
$12.73
Follow $NTLA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NTLA by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredMon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET · NTLA
MethodologyNTLA
Intellia Therapeutics Inc
Mon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
44/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NTLA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Intellia Therapeutics Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESListed since
2016
Employees
377
Country
US
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$12.35
Day high
$12.88
Day low
$11.85
Previous close
$12.26
52W high
$27.98
-54.50% from high
52W low
$8.04
24% of range
Market cap
$1.7B
EPS
$-3.3565
Beta
2.43
Shares out
140.1M
Volume
5M
1.22× rel vol
Avg volume
4.1M
VWAP
$12.43
Price history computed in-house
1W
+11.47%
1M
-0.08%
3M
-26.97%
1Y
-36.22%
YTD
+41.60%
SMA 50 $12.06 · above
SMA 200 $12.87 · below
52W position 24%
NTLA overview
Related filings and maps
Public disclosures
Congress activity in NTLA
1 filers · 4 buys · 6 sells (0 labeled S (partial)) · Dec 9, 2019 to Feb 28, 2022 · House 10 / Senate 0
All available history · Latest 5 of 10 lines · Read 2026-10-05T22:51:37.712Z
Official filing ↗
Intellia Therapeutics, Inc. · Transaction Oct 29, 2021 · Filed Oct 30, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Sep 20, 2021 · Filed Oct 1, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Jul 21, 2021 · Filed Aug 7, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Jan 15, 2021 · Filed Jan 31, 2021 · $1,001 to $15,000
Federal contracts
NTLA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NTLA in this window.
Lobbying spend
NTLA lobbying filings, year to date.
Registered lobbying filings matched to Intellia Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NTLA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NTLA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.